Management of QT Interval Prolongation

Initial Assessment and Risk Stratification

The American College of Cardiology recommends that QTc is considered prolonged when >430 ms in males and >450 ms in females 1
Fridericia's formula (QT/RR^1/3) is recommended for heart rate correction, as it provides less over- and under-correction in patients with tachycardia or bradycardia compared to Bazett's formula 2, 1
A QTc >500 ms or an increase >60 ms from baseline significantly increases the risk of torsades de pointes 1, 1
The severity of QT prolongation can be graded, with Grade 1: QTc 450-480 ms, Grade 2: QTc 481-500 ms, Grade 3: QTc >501 ms, and Grade 4: QTc ≥501 ms with torsades de pointes or sudden death 1
Non-modifiable risks for QT prolongation include female sex, advancing age, and genetic predisposition to long QT syndrome 3
Modifiable risks include hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, heart failure, concomitant QT-prolonging medications, and drug-drug interactions 3, 1

For QTc 450-500 ms, the American College of Cardiology recommends obtaining a baseline ECG, identifying all QT-prolonging medications, and correcting electrolyte abnormalities 1
For QTc >500 ms, immediate discontinuation of all QT-prolonging medications, initiation of continuous cardiac monitoring, and administration of 2g IV magnesium sulfate are recommended 1

The American College of Cardiology recommends avoiding high-risk QT-prolonging drugs, including antiarrhythmics (Class IA and Class III), antibiotics (macrolides and fluoroquinolones), antipsychotics (haloperidol, thioridazine, chlorpromazine), and antiemetics (ondansetron) 1
Safe alternatives, such as benzodiazepines and metoclopramide, can be used instead of QT-prolonging medications 1

Baseline ECG and electrolyte measurements are recommended before initiating QT-prolonging medications 2, 4
Ongoing monitoring of ECG and electrolytes is necessary during treatment with QT-prolonging medications 4, 1

Cancer patients receiving QT-prolonging chemotherapeutic agents require baseline ECG and periodic monitoring 2
Patients with congenital long QT syndrome should avoid QT-prolonging medications and receive beta blockers as first-line therapy 3
Young women with LQT2 and QTc >500 ms are at increased risk of sudden cardiac arrest, especially in the postpartum period 3

Ondansetron is specifically identified as a QT-prolonging medication that should be avoided in patients with baseline QT prolongation, according to the American College of Cardiology 5
Dolasetron can cause serious cardiac arrhythmias including QT prolongation, heart block, and torsades de pointes in patients with prolonged QTc, as reported in Circulation 6
Prochlorperazine is explicitly contraindicated in patients on dofetilide due to QT-prolonging effects, as stated in Circulation 6
Prochlorperazine is listed among important medications that prolong the QTc interval and should be avoided, according to the American College of Cardiology 5
Domperidone is specifically identified as a QT-prolonging antiemetic that should be avoided in at-risk patients, as reported by the American College of Cardiology 5

Metoclopramide does not appear in any of the extensive lists of QT-prolonging medications across multiple cardiology guidelines, including Circulation and the European Heart Journal 6, 7, 8, 9, 10, 11
Metoclopramide does not cause bradycardia or worsen conduction abnormalities, as reported in the European Heart Journal 11
The recommended dosing for metoclopramide is 10 mg IV/PO every 6-8 hours as needed, according to Circulation 9
Benzodiazepines, such as lorazepam, are recommended as safe alternatives for nausea management in patients at risk for QT prolongation, with a dosing recommendation of 0.5-1 mg IV/PO every 6-8 hours as needed, as reported in Circulation and the European Heart Journal 9, 10

Correcting hypokalemia and hypomagnesemia immediately before administering any antiemetic is crucial, as these are modifiable risk factors that significantly increase torsades de pointes risk, according to Circulation 6
Drug-drug interactions should not be overlooked, as many medications used in hospitalized patients also prolong QT, as reported in Circulation and the American College of Cardiology 5, 6, 7

The British Thoracic Society guidelines acknowledge metoclopramide only in the context of combination therapy with bedaquiline, not as a standalone risk 12

For patients with QTc >500 ms or increase >60 ms from baseline, discontinue all QT-prolonging medications immediately, and use metoclopramide or benzodiazepines for nausea management 13

When using metoclopramide, exercise caution in scenarios involving polypharmacy, reviewing all concurrent medications for QT-prolonging agents, as recommended by the Journal of the National Comprehensive Cancer Network 14
Ensure potassium >4.0 mEq/L and magnesium >2.0 mg/dL before metoclopramide administration, as recommended by Circulation 15
Obtain a baseline ECG in patients with cardiac disease or on other QT-prolonging medications, as recommended by the European Heart Journal and the Journal of the National Comprehensive Cancer Network 13, 14